Structure Therapeutics, Inc. Sponsored ADR (GPCR) AI Stock Analysis

• Market Cap: $4.45B
• Dividend Yield: N/A
• Average Volume (3M): 929.03K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.20
• Revenue Growth: N/A
• EPS Growth: -64.91%
• Country: US
• Employees: 163
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 70,639,190
• 10 Day Avg. Volume: 787,508
• 30 Day Avg. Volume: 929,029
• PEG Ratio: -11.37
• Price to Book (P/B): 2.72
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -18.23
• Enterprise Value/Market Cap: 0.64
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -4.12K
• Enterprise Value/Ebitda: -17.94
• 1Y Price Target: $109.23
• Price Target Upside: 73.44% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 14
• EPS Forecast (FY): -1.92
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: $66.00 ▲(4.80% Upside)
• Action: Reiterated Date: 02/27/26
• Date: Action: Reiterated 02/27/26

The score is primarily driven by mixed financials: strong solvency and low leverage are outweighed by being pre-revenue with rising losses and a high cash burn rate. Technicals are weak (below key short-term averages with negative MACD), while recent corporate events are a notable positive catalyst (licensing cash infusion and supportive clinical results). Valuation provides limited support due to negative earnings and no dividend data.

Positive Factors

Balance sheet strength

Minimal leverage and a materially larger equity base provide durable financial flexibility to fund clinical programs and weather biotech cyclical risk. This reduces near-term solvency pressure, supports partnering or licensing negotiations, and lengthens runway vs high-debt peers.

Non-dilutive licensing cash infusion

A $100M non-dilutive payment with royalties is a structural capital injection and partner validation that preserves company equity and pipeline control. It creates an early revenue cadence and optionality to fund R&D or de-risk specific programs without immediate dilution.

Advancing clinical program (Phase 2b positive results)

Robust Phase 2b/ACCESS data and a clear path to Phase 3 materially de-risk the lead program over the medium term. Success in later-stage trials would substantively increase commercial optionality, partner appeal, and the likelihood of future revenue streams and milestone payments.

Negative Factors

Pre-revenue operations

Being pre-revenue means all value depends on clinical and regulatory outcomes rather than product sales. This makes cash needs and valuation binary on trial success, increasing long-term financing risk and making long-horizon sustainability contingent on future approvals or partnerships.

High and rising cash burn

Deep and rising negative operating and free cash flow signals heavy capital consumption to advance trials. Persistent high burn shortens runway absent new funding, may force program prioritization, and constrains strategic flexibility over the 2–6 month horizon without sustained financing.

Dependence on capital markets

A large recent equity offering underscores reliance on external capital to fund operations. While it provides near-term resources, ongoing dependence on markets can dilute shareholders, signal funding necessity, and expose plans to market conditions, affecting long-term strategic choices.

Structure Therapeutics, Inc. Sponsored ADR Business Overview & Revenue Model

Company Description

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. Its lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. The company is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist, targeting apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension; and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was founded in 2016 and is headquartered in South San Francisco, California.

How the Company Makes Money

Structure Therapeutics, Inc. generates revenue through the development and commercialization of its drug candidates. The company makes money by advancing its compounds through clinical trials and seeking regulatory approval for market entry. Once approved, these drugs can be licensed or sold to pharmaceutical companies or healthcare providers, generating income through sales, royalties, or milestone payments. Additionally, the company may engage in strategic partnerships or collaborations with other biopharmaceutical firms, which can provide funding, shared resources, and expertise in exchange for a share in the profits or rights to market the developed therapies. These partnerships and collaborations often play a significant role in the company's revenue model, offering both financial support and expanded market reach.

Structure Therapeutics, Inc. Sponsored ADR Financial Statement Overview

Summary

Balance sheet strength (minimal leverage and materially higher equity) supports financial flexibility, but this is offset by pre-revenue operations, widening net losses, and accelerating operating/free cash burn.

Income Statement

The company is still pre-revenue (revenue is $0 across all reported years), so results are driven by operating spend rather than commercial execution. Losses have widened over time, with net loss increasing from about $40.0M (2021) to about $141.2M (2025), indicating a rising cash burn profile as R&D scales. While this trajectory can be normal for biotech, the lack of revenue and expanding losses weigh heavily on income-statement quality and near-term profitability.

Balance Sheet

The balance sheet is a clear strength: leverage is minimal, with debt staying very low and debt-to-equity around ~0.4% in 2024–2025. Equity has expanded materially (from negative levels in 2020–2022 to ~$1.52B in 2025), suggesting substantial capital raises and improved solvency. The main weakness is that returns remain negative given ongoing losses, but overall financial flexibility appears strong due to low debt and a large equity base.

Cash Flow

Cash generation remains weak, with operating cash flow consistently negative and worsening to about -$222.2M in 2025 (from about -$32.2M in 2021). Free cash flow is also deeply negative (about -$225.8M in 2025), and the year-over-year change in free cash flow has been volatile (including a sharp deterioration in earlier years and a reported improvement in 2025 that still leaves substantial burn). A positive point is that free cash flow broadly tracks net losses (roughly one-to-one), suggesting limited non-cash distortion—but the absolute burn level remains the key risk.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	0.00	0.00	0.00	0.00
EBITDA	-139.35M	-157.24M	-102.48M	-52.28M	-37.62M
Net Income	-141.20M	-122.53M	-89.62M	-51.32M	-40.01M
Balance Sheet
Total Assets	1.58B	903.33M	482.02M	97.84M	111.16M
Cash, Cash Equivalents and Short-Term Investments	1.45B	883.52M	467.32M	90.84M	107.31M
Total Debt	6.49M	3.86M	5.45M	260.00K	621.00K
Total Liabilities	67.54M	38.49M	29.05M	212.99M	175.89M
Stockholders Equity	1.52B	864.84M	452.97M	-115.14M	-64.73M
Cash Flow
Free Cash Flow	-225.81M	-117.93M	-81.66M	-46.27M	-33.37M
Operating Cash Flow	-222.20M	-116.64M	-79.49M	-46.12M	-32.16M
Investing Cash Flow	89.80M	-358.91M	-268.34M	-62.11M	17.86M
Financing Cash Flow	762.52M	515.26M	451.53M	29.01M	103.25M

Structure Therapeutics, Inc. Sponsored ADR Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 62.98
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GPCR, the sentiment is Neutral. The current price of 62.98 is below the 20-day moving average (MA) of 73.56, below the 50-day MA of 74.42, and above the 200-day MA of 38.12, indicating a neutral trend. The MACD of -3.36 indicates Positive momentum. The RSI at 33.49 is Neutral, neither overbought nor oversold. The STOCH value of 12.64 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for GPCR.

Structure Therapeutics, Inc. Sponsored ADR Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
STOK	61 Neutral	$2.08B	55.18	15.02%	―	1128.17%	―
GPCR	54 Neutral	$4.45B	-17.24	-25.31%	―	―	-64.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SNDX	51 Neutral	$1.91B	-6.59	-129.32%	―	597.19%	0.45%
ZYME	50 Neutral	$1.76B	-27.50	-18.46%	―	116.21%	43.93%

Structure Therapeutics, Inc. Sponsored ADR Corporate Events

Structure Therapeutics inks major GLP-1 licensing deal

On December 30, 2025, Gasherbrum Bio, a subsidiary of Structure Therapeutics, entered into a non-exclusive licensing agreement with Genentech and Roche, granting them rights under certain Gasherbrum patents covering a distinct class of oral GLP-1 receptor agonists to develop and commercialize products containing Genentech’s proprietary compound CT-996. In return, Gasherbrum will receive a one-time $100 million payment within 30 days of signing and low single-digit royalties on net sales of CT-996 products until the relevant patents expire or a specified earlier date, while retaining full control over its own metabolic pipeline, as the license expressly does not encumber Structure’s ongoing programs, including aleniglipron and other GLP-1, dual amylin/calcitonin, and GIPR/GCGR modulators, and preserves Gasherbrum’s ability to terminate the deal in the event of material breach or patent challenges, providing a significant non-dilutive capital infusion without ceding broader strategic or patent prosecution rights.

The most recent analyst rating on (GPCR) stock is a Hold with a $73.00 price target. To see the full list of analyst forecasts on Structure Therapeutics, Inc. Sponsored ADR stock, see the GPCR Stock Forecast page.

Structure Therapeutics Announces $650 Million Public Offering

On December 9, 2025, Structure Therapeutics, Inc. entered into an underwriting agreement to issue and sell American Depositary Shares (ADSs) and pre-funded warrants in a public offering. The offering is expected to generate approximately $650 million in gross proceeds, with the closing anticipated on December 11, 2025, subject to customary conditions. This move is part of the company’s strategy to raise capital, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (GPCR) stock is a Buy with a $99.00 price target. To see the full list of analyst forecasts on Structure Therapeutics, Inc. Sponsored ADR stock, see the GPCR Stock Forecast page.

Structure Therapeutics Announces Positive Clinical Trial Results

On December 8, 2025, Structure Therapeutics announced positive results from its ACCESS clinical program for aleniglipron, a once-daily oral GLP-1 receptor agonist for obesity treatment. The Phase 2b ACCESS study showed significant weight loss with a 120 mg dose, while the exploratory ACCESS II study demonstrated even greater weight loss with a 240 mg dose. The findings support advancing to Phase 3 trials in mid-2026, potentially offering a scalable and accessible treatment option for obesity.

The most recent analyst rating on (GPCR) stock is a Buy with a $50.00 price target. To see the full list of analyst forecasts on Structure Therapeutics, Inc. Sponsored ADR stock, see the GPCR Stock Forecast page.